ERBB2 and lung cancer: Consequently, the genomic analysis of patients who belong to the above categories and lack alterations in EGFR, ERBB2 (HER2), ALK, ROS1, RET, NTRK1/2/3, KRAS, or NRAS genes has significant potential for identifying new drivers of lung cancer pathogenesis.